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EQ-5D, DLQI and PASI in psoriasis
This large sample study analysed the relationship between 
generic, disease-specific and clinical measures in patients 
with moderate to severe psoriasis. In total, 2450 patients 
(1479 men and 971 women) were included. Median EuroQol 
5D (EQ-5D), Dermatology Life Quality Index (DLQI) and 
Psoriasis Area and Severity Index (PASI) scores were 0.769, 
4 and 4.7, respectively. Patients with psoriasis had a sig-
nificantly lower EQ-5D compared with the defined general 
population. EQ-5D correlated moderately with DLQI (–0.55) 
and weakly with PASI (–0.25) (P < 0.001). When assessing 
psoriasis treatments and making decisions about treatment 
guidelines and resource allocation, EQ-5D, DLQI and PASI 
provide a useful set of complementary tools, answering to 
different needs. If EQ-5D is not included in the original trial 
the second-best option in cost-effectiveness studies is to use 
mapping between DLQI and EQ-5D. Br J Dermatol 2012; 
166: 797–802.
Long-term efficacy of ustekinumab in 
moderate-to-severe psoriasis
Kimball et al. report the 76-week to 3-year results of the 
PHOENIX trial. Overall, 79.8% of ustekinumab-treated 
patients remained in the study for 3 years. PASI 75 and 
Physician Global Assessment response rates were main-
tained. At year 3, 80.9% (45 mg) and 82.7% (90 mg) of week 
40 responders continuing treatment every 12 weeks achieved 
a PASI 75 response, while 36.1% (45 mg) and 45.5% (90 
mg) achieved a PASI 90 response. Among partial responders 
adjusted to dosing every 8 weeks, 50.9% (45 mg) and 52.0% 
(90 mg) had a PASI 75 response at year 3. No dose response 
was observed in rates of adverse events or overall infections, 
nor was there evidence of cumulative organ toxicity. These 
results continue to support the favourable benefit–risk profile 
of ustekinumab in the treatment of moderate-to-severe pso-
riasis with continuous, stable maintenance dosing through 3 
years of therapy. Br J Dermatol 2012; 166: 861–72.
Nonfatal cardiovascular disease in women 
with psoriasis
This study examined the association between psoriasis and 
nonfatal cardiovascular disease (CVD) in a population of 
96,008 participants from the Nurses’ Health Study II. The 
results demonstrated a considerably increased risk of nonfa-
tal CVD, particularly myocardial infarction, in women with 
psoriasis, even after adjusting for the traditional cardiovas-
cular risk factors. Given the limited cases, the power was not 
sufficient to evaluate the association between psoriasis and 
risk of stroke. The magnitude of the association was higher in 
those with concomitant psoriatic arthritis, diagnosis under 
40 years of age or duration of psoriasis of 9 or more years. 
Br J Dermatol 2012; 166: 811–18.
ESR as an independent prognostic factor in MF
Hallermann et al. present the erythrocyte sedimentation rate 
(ESR) as a new prognostic marker for mycosis fungoides (MF). 
In a retrospective monocentre study, sex, age at time of diag-
nosis, age-adjusted ESR and anaemia were correlated with 
survival data in 97 patients with MF. The only factor associated 
with prognosis was the ESR. It also had an impact on overall 
survival and disease-specific survival (P < 0.001). Br J Dermatol 
2012; 166: 873–74.
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